310 related articles for article (PubMed ID: 29700965)
21. A Bayesian design for finding optimal biological dose with mixed types of responses of toxicity and efficacy.
Zhang D; Xu J
Contemp Clin Trials; 2023 Apr; 127():107113. PubMed ID: 36758934
[TBL] [Abstract][Full Text] [Related]
22. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
Yuan Y; Lin R; Li D; Nie L; Warren KE
Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
[TBL] [Abstract][Full Text] [Related]
23. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
Yang C; Li Y
Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
[TBL] [Abstract][Full Text] [Related]
25. The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.
Chiuzan C; Dehbi HM
Clin Trials; 2024 Jun; 21(3):350-357. PubMed ID: 38618916
[TBL] [Abstract][Full Text] [Related]
26. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
27. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
Takahashi A; Suzuki T
Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
[TBL] [Abstract][Full Text] [Related]
28. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
Li P; Liu R; Lin J; Ji Y
J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
[TBL] [Abstract][Full Text] [Related]
29. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
Hirakawa A
Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
[TBL] [Abstract][Full Text] [Related]
30. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
Takeda K; Xia Q; Liu S; Rong A
Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
[TBL] [Abstract][Full Text] [Related]
31. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
32. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
33. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
[TBL] [Abstract][Full Text] [Related]
34. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
35. Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN).
Zhao Y; Yuan Y; Korn EL; Freidlin B
Clin Cancer Res; 2024 Feb; 30(4):673-679. PubMed ID: 38048044
[TBL] [Abstract][Full Text] [Related]
36. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
37. Optimal dose escalation methods using deep reinforcement learning in phase I oncology trials.
Matsuura K; Sakamaki K; Honda J; Sozu T
J Biopharm Stat; 2023 Sep; 33(5):639-652. PubMed ID: 36717962
[TBL] [Abstract][Full Text] [Related]
38. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials.
Lin R; Yin G; Shi H
Biostatistics; 2023 Apr; 24(2):277-294. PubMed ID: 34296266
[TBL] [Abstract][Full Text] [Related]
39. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
[TBL] [Abstract][Full Text] [Related]
40. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]